Two Sigma Investments LP increased its holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 12.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 273,352 shares of the biopharmaceutical company's stock after buying an additional 29,773 shares during the quarter. Two Sigma Investments LP owned about 0.36% of Xenon Pharmaceuticals worth $10,715,000 at the end of the most recent reporting period.
Several other large investors have also recently added to or reduced their stakes in XENE. Quarry LP bought a new position in shares of Xenon Pharmaceuticals in the fourth quarter worth $78,000. Blue Trust Inc. lifted its holdings in Xenon Pharmaceuticals by 140.3% in the fourth quarter. Blue Trust Inc. now owns 2,422 shares of the biopharmaceutical company's stock worth $95,000 after purchasing an additional 1,414 shares during the period. Avior Wealth Management LLC acquired a new stake in Xenon Pharmaceuticals in the fourth quarter worth about $101,000. KBC Group NV grew its position in Xenon Pharmaceuticals by 39.8% in the 4th quarter. KBC Group NV now owns 2,742 shares of the biopharmaceutical company's stock valued at $107,000 after buying an additional 780 shares in the last quarter. Finally, Magnetar Financial LLC acquired a new position in Xenon Pharmaceuticals during the 4th quarter valued at about $210,000. 95.45% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
A number of analysts have recently weighed in on the stock. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Xenon Pharmaceuticals in a research note on Tuesday, February 11th. They issued a "buy" rating and a $67.00 price target for the company. Wall Street Zen downgraded Xenon Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Wednesday, May 21st. HC Wainwright reaffirmed a "buy" rating and set a $53.00 price target on shares of Xenon Pharmaceuticals in a research note on Tuesday, May 13th. Wells Fargo & Company lowered their price target on Xenon Pharmaceuticals from $50.00 to $47.00 and set an "overweight" rating on the stock in a research report on Tuesday, May 13th. Finally, William Blair restated an "outperform" rating on shares of Xenon Pharmaceuticals in a report on Monday, May 5th. One research analyst has rated the stock with a sell rating and twelve have given a buy rating to the stock. According to MarketBeat.com, Xenon Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $54.82.
View Our Latest Analysis on XENE
Xenon Pharmaceuticals Price Performance
Shares of XENE traded up $0.71 during trading hours on Thursday, hitting $29.20. 1,057,114 shares of the company were exchanged, compared to its average volume of 530,590. The company has a market capitalization of $2.24 billion, a PE ratio of -10.35 and a beta of 1.21. The firm has a fifty day simple moving average of $33.27 and a 200-day simple moving average of $37.23. Xenon Pharmaceuticals Inc. has a one year low of $26.74 and a one year high of $46.00.
Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The biopharmaceutical company reported ($0.83) earnings per share for the quarter, beating analysts' consensus estimates of ($0.90) by $0.07. The company had revenue of $7.50 million during the quarter, compared to analyst estimates of $1.64 million. During the same quarter last year, the business earned ($0.62) EPS. Sell-side analysts expect that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current year.
Xenon Pharmaceuticals Profile
(
Free Report)
Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.
Featured Stories
Before you consider Xenon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.
While Xenon Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
